Chronic hepatitis D at a standstill: where do we go from here?

被引:36
作者
Ciancio, Alessia [1 ]
Rizzetto, Mario [1 ]
机构
[1] Univ Turin, Molinette Hosp, Div Gastroenterol, I-10126 Turin, Italy
关键词
CHRONIC DELTA-HEPATITIS; INJECTION-DRUG USERS; B-VIRUS; PEGYLATED INTERFERON-ALPHA-2B; ENVELOPE PROTEIN; FOLLOW-UP; LAMIVUDINE; REPLICATION; PRENYLATION; PREVALENCE;
D O I
10.1038/nrgastro.2013.164
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Immigration is fuelling a new reservoir of hepatitis D virus (HDV) in Europe, and hepatitis D still represents an important medical problem in the USA. The disease continues to be a major medical scourge in the developing world, in particular in countries such as Pakistan, Mongolia and Mauritania. New therapeutic strategies are being developed to disrupt interactions between HDV and its viral partner HBV, or with the host. Blocking or modifying the hepatitis B surface antigen (HBsAg) might interfere with the uptake or release of the hepatitis D virion; interference with host-mediated post-translational changes of proteins that are crucial to the HDV life cycle, such as prenylation, is another potential therapeutic option. At present, however, the only realistic option is to optimize IFN-alpha therapy. As eradication of HBsAg is the ultimate end point of therapy, long-term interferon administration might be required, raising an issue of tolerance in patients. Treatment with IFN-lambda is a potential alternative approach to IFN-alpha; treatment of hepatitis C with this cytokine seems to cause fewer adverse effects than IFN-alpha and, therefore, might be more suitable for long-term treatment of HDV.
引用
收藏
页码:68 / 71
页数:4
相关论文
共 45 条
[1]   Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange [J].
Abou-Jaoude, Georges ;
Sureau, Camille .
JOURNAL OF VIROLOGY, 2007, 81 (23) :13057-13066
[2]   Lamivudine-associated remission of chronic hepatitis delta [J].
Andreone, P ;
Spertini, F ;
Negro, F .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (07) :598-598
[3]   Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users [J].
Bialek, SR ;
Bower, WA ;
Mottram, K ;
Purchase, D ;
Nakano, T ;
Nainan, O ;
Williams, IT ;
Bell, BP .
JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2005, 82 (03) :468-478
[4]   In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus [J].
Bordier, BB ;
Ohkanda, J ;
Liu, P ;
Lee, SY ;
Salazar, FH ;
Marion, PL ;
Ohashi, K ;
Meuse, L ;
Kay, MA ;
Casey, JL ;
Sebti, SM ;
Hamilton, AD ;
Glenn, JS .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :407-414
[5]   A prenylation inhibitor prevents production of infectious hepatitis delta virus particles [J].
Bordier, BB ;
Marion, PL ;
Ohashi, K ;
Kay, MA ;
Greenberg, HB ;
Casey, JL ;
Glenn, JS .
JOURNAL OF VIROLOGY, 2002, 76 (20) :10465-10472
[6]   Efficacy of peginterferon alpha-2b in chronic hepatitis delta:: Relevance of quantitative RT-PCR for follow-up [J].
Castelnau, Corinne ;
Le Gal, Frederic ;
Ripault, Marie-Pierre ;
Gordien, Emmanuel ;
Martinot-Peignoux, Michelle ;
Boyer, Nathalie ;
Pham, Bach-Nga ;
Maylin, Sarah ;
Bedossa, Pierre ;
Deny, Paul ;
Marcellin, Patrick ;
Gault, Elyanne .
HEPATOLOGY, 2006, 44 (03) :728-735
[7]   Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action [J].
Chang, J ;
Taylor, JM .
JOURNAL OF VIROLOGY, 2003, 77 (17) :9728-9731
[8]   HEPATITIS PEG-IFN for the treatment of hepatitis D [J].
Ciancio, Alessia ;
Rizzetto, Mario .
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2011, 8 (06) :304-306
[9]   The increasing prevalence of hepatitis delta virus (HDV) infection in South London [J].
Cross, Timothy J. S. ;
Rizzi, Paolo ;
Horner, Mary ;
Jolly, Anita ;
Hussain, Munther J. ;
Smith, Heather M. ;
Vergani, Diego ;
Harrison, Phillip M. .
JOURNAL OF MEDICAL VIROLOGY, 2008, 80 (02) :277-282
[10]  
Erhardt A, 2003, Z GASTROENTEROL, V41, P523, DOI 10.1055/s-2003-39648